MedApp S.A. has strengthened its cooperation with NEO Hospital Group. As part of the signed agreement, the Group’s Szpital na Klinach will use the CarnaLife Holo technology for 3D visualization of imaged medical data in the implementation of a newresearch and development project. Its goal is to develop a new method for the surgical treatment of endometrial and cervical cancers.
“The coronavirus pandemic has drastically affected the implementation of prevention programs. Diagnostics have also suffered greatly. We will emerge from the pandemic with an alarming scale of health debt. We must look for methods and tools to improve the effectiveness of treatment of oncology patients. Our research program, based on minimally invasive therapeutic methods, modern equipment and innovative systems supporting the process of treatment planning, creates such an opportunity for women with cervical and endometrial cancer,” says Joanna Szyman, CEO of NEO Hospital Group.
The CarnaLife Holo solution will be used by NEO Hospital in a project concerning surgical treatment of cervical and endometrial cancer. The surgeries will be performed at Szpital na Klinach in Kraków under funding from the Malopolska Regional Operational Program for 2014 -2020. Under the project, the Hospital will perform 200 procedures using the DaVinci robot. The treatment will be free of charge for the patients.
“CarnaLife Holo streamlines diagnostic processes, which, especially in difficult and complex procedures, can impact the physician’s precision and safety. We are pleased that our innovations are increasingly used in daily medical practice, supporting medics during surgical procedures,” says Krzysztof Mędrala, CEO of MedApp.
Read more See similar articles:
We are looking for companies and individuals interested in distributing MedApp’s medical technology.
CarnaLife Holo is a breakthrough technology for 3D visualization of imaged medical data which supports the planning and performance of medical procedures. With the help of Microsoft’s HoloLens 2, the physician can see in real space a three-dimensional hologram reflecting the structure of the imaged anatomical area.
MedApp after Q2 2022: Another Quarter of Geographic and Product Expansion
MedApp, a publicly listed company in the innovative medical technology industry, recorded net sales of PLN 1,588 million, PLN 878 thousand EBITDA earnings and PLN 405 thousand net profit in the second quarter of 2022, despite the increasing uncertainty in the business environment and the challenges facing medical facilities.
MedApp is the laureate of the Special Award of PARP and NCBR
During the Gala of the 24th edition of the Polish Product of the Future competition, we received a special award from the Polish Agency for Enterprise Development and the National Center for Research and Development!